These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center. Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center. Jang K; Ahn J; Sohn J; Hwang DD Clin Ophthalmol; 2020; 14():3211-3218. PubMed ID: 33116371 [TBL] [Abstract][Full Text] [Related]
6. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278 [TBL] [Abstract][Full Text] [Related]
7. Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Woo SJ; Han JM; Ahn J; Heo JW; Yu HG; Chung H; Song J; Park KU; Park KH Retina; 2012 Apr; 32(4):667-71. PubMed ID: 22307220 [TBL] [Abstract][Full Text] [Related]
8. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept. Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277 [TBL] [Abstract][Full Text] [Related]
9. Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France. Baudin F; Benzenine E; Mariet AS; Bron AM; Daien V; Korobelnik JF; Quantin C; Creuzot-Garcher C JAMA Ophthalmol; 2018 Dec; 136(12):1352-1358. PubMed ID: 30242325 [TBL] [Abstract][Full Text] [Related]
11. Safety of simultaneous bilateral intravitreal versus unilateral anti-vasculo-endothelial growth factors injection in an operating room setting. Jeeva IK; Masud S; Siddiqui MAR; Fahad HM Pak J Med Sci; 2022; 38(8):2324-2330. PubMed ID: 36415252 [TBL] [Abstract][Full Text] [Related]
12. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Xu Y; Tan CS Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451 [TBL] [Abstract][Full Text] [Related]
13. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept. Forooghian F; Albiani DA; Kirker AW; Merkur AB Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032 [TBL] [Abstract][Full Text] [Related]
14. Bilateral intravitreal injection of antivascular endothelial growth factor therapy. Mahajan VB; Elkins KA; Russell SR; Boldt HC; Gehrs KM; Weingeist TA; Stone EM; Abràmoff MD; Liu D; Folk JC Retina; 2011 Jan; 31(1):31-5. PubMed ID: 21187731 [TBL] [Abstract][Full Text] [Related]
15. Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina. Terzić S; Pilavdžić A; Nadarević Vodenčarević A Med Glas (Zenica); 2015 Aug; 12(2):202-5. PubMed ID: 26276660 [TBL] [Abstract][Full Text] [Related]
16. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection. Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794 [TBL] [Abstract][Full Text] [Related]
18. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Cheung CS; Wong AW; Lui A; Kertes PJ; Devenyi RG; Lam WC Ophthalmology; 2012 Aug; 119(8):1609-14. PubMed ID: 22480743 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052 [TBL] [Abstract][Full Text] [Related]
20. Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting. Hasler PW; Bloch SB; Villumsen J; Fuchs J; Lund-Andersen H; Larsen M Acta Ophthalmol; 2015 Mar; 93(2):122-5. PubMed ID: 25403735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]